If you supply, mold, machine, assemble, or package for a medical device OEM, at least one of your competitors has probably changed ownership recently — and the outsourcing base looks materially different than it did a few years ago. Join MedWorld Advisors to learn who's doing the buying, why certain CDMOs command higher valuations than other medtech suppliers, and what it means to compete against consolidated, well-capitalized platforms.

MedWorld Advisors served as exclusive sell-side advisor to Unitron Group B.V. on its sale to Nolato AB. The combination brings Unitron's manufacturing capability into Nolato's global medtech platform — a strong outcome for shareholders and a strong home for the business.

While AI is a fantastic tool to use during M&A transactions, it doesn’t replace the situational intelligence provided by human transaction advisors.

The 2026 Top 10 Companies list is less a ranking than a map of an industry transforming itself in public.

Capability-building medtech acquisitions are more relevant to the market than headline-grabbing transformational ones. Read more in our column, MedTech Mindset, in Today’s Medical Developments Magazine.

The most important takeaway from the 2026 MPO Top 30 report is not embedded in any one transaction but rather the pattern among the ranked firms.

Medtech companies must assess where artificial intelligence creates value at each stage of the product lifecycle.

Watch Dave Sheppard give the 2026 ODT Forum State of the Industry. This session provides a comprehensive overview of the happenings within the orthopedic device manufacturing industry. Supply chain, M&A, and other related topics critical to both OEMs and their supply partners are covered.

The $75 billion orthopedic market is growing, but pricing pressure throughout the supply chain is intensifying.

With the global environment for medical device manufacturing, cross-border deals are common and may provide for a unique definition for success.

When connected medical devices meet state-sponsored hackers, the C-suite owns the outcome.

Medtech executives or board members with an eye toward a future liquidity event should start building intrinsic value in their respective organizations now.

Understand what drives value in today’s medtech M&A market, from multiples and EBITDA to buyer strategy and deal timing.

The lasting impression from AAOS 2026 is that the orthopedic industry is not waiting for the future.

Manufacturing-related AI can contribute to value because it improves performance in ways buyers can underwrite.

C-suites are being forced to include tariff dynamics into their short-term and long-term strategies.